Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one
million people die annually from HBV-related causes, including liver cancer. Although there …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

Background & Aims It has been proposed that serum hepatitis B core-related antigen
(HBcrAg) reflects intrahepatic covalently closed circular (ccc) DNA levels. However, the …

Background & Aims Loss of serum HBsAg is a hallmark of spontaneous and therapy
induced resolution of HBV infection, since it generally reflects a profound decrease in viral …

HBV infection remains a leading cause of death worldwide. IFN-α inhibits viral replication in
vitro and in vivo, and pegylated IFN-α is a commonly administered treatment for individuals …

BACKGROUND & AIMS: Currently approved antivirals rarely cure hepatitis B virus (HBV)
infection. Therefore additional therapeutic strategies interfering with other viral replication …

Chronic hepatitis B virus (HBV) infection continues to be a major health burden worldwide; it
can cause various degrees of liver damage and is strongly associated with the development …

The template of hepatitis B virus (HBV) transcription, the covalently closed circular DNA
(cccDNA), plays a key role in the life-cycle of the virus and permits the persistence of …

BACKGROUND & AIMS: The accurate identification of inactive (serum HBV-DNA
persistently≤ 2000 IU/mL) hepatitis B virus (HBV) carriers (IC) is difficult because of wide …

BACKGROUND & AIMS: The quantifiable level of HBsAg has been suggested as a predictor
of treatment response in chronic hepatitis B. However, there is limited information on HBsAg …